Amicus Therapeutics, Inc., is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders. The Company�s development programs include next-generation enzyme replacement therapies for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharoidosis Type I. The Company is also developing small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Patients with LSDs who are receiving ERT, the infused exogenous protein may unfold and lose activity at any stage in the process from the infusion bag to the bloodstream, to the eventual uptake into cells and tissue. The Company�s Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop its next-generation ERTs by co-formulating therapeutic enzymes with its pharmacological chaperones.